Itaphyte 100 Capsule contains Itraconazole 100 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is primarily indicated for the treatment of various fungal infections, including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itaphyte 100 Capsule is administered orally and demonstrates excellent bioavailability when taken with food, ensuring optimal systemic absorption. The drug is metabolized predominantly by the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Rare but serious side effects may include hepatotoxicity and congestive heart failure exacerbation. Monitoring liver function tests during prolonged therapy is recommended. Itaphyte 100 Capsule should be used under medical supervision, with dosage and duration tailored according to the specific fungal infection and patient response. It is contraindicated in patients with known hypersensitivity to itraconazole and should be avoided during pregnancy unless deemed essential by a healthcare provider.